ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/fluoropyrimidine
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/fluoropyrimidine
40
trial(s) found.
NCT06926868
Advanced
Phase 2 / Phase 3
Not yet recruiting
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable,or Metastatic Triple-negative Breast Cancer (TNBC)or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment (
CA244-0008
)
bispecific EGFR/ERBB3 antibody
+ fluoropyrimidine
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ fluoropyrimidine
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
+ fluoropyrimidine
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
+ fluoropyrimidine
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06538610
Advanced
NA
Recruiting
Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy (
CTNZ-2022-08
)
fluoropyrimidine
Gastrointestinal cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
+ fluoropyrimidine
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
+ fluoropyrimidine
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06393374
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery (
2870-012
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ fluoropyrimidine
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06360354
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
PRMT5 inhibitor
+ fluoropyrimidine
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06312176
Advanced
Phase 3
Recruiting
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (
2870-010
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ fluoropyrimidine
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06247995
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Multi-center Trial of [177Lu]Lu-NeoB in Combination With Capecitabine in Adult Patients With Gastrin Releasing Peptide Receptor Positive, Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (
NeoB-Cap1
)
fluoropyrimidine
radioligand,GRPR-targeting
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
+ fluoropyrimidine
Biliary tract cancer
Cancer
Gastric cancer
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06112379
Curative
Phase 3
Recruiting
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (
D926QC00001
; TROPION-Breast04)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
+ fluoropyrimidine
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (WITHDRAWN)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT06109779
Curative
Phase 3
Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) (
D7025C00001
)
bispecific PD-1/TIGIT antibody
placebo
+ fluoropyrimidine
Biliary tract cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
+ fluoropyrimidine
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
+ fluoropyrimidine
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05647122
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (
EGRET
)
anti EGFR/cMET antibody-drug conjugate
+ fluoropyrimidine
Head and neck squamous cell carcinoma
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
+ fluoropyrimidine
Colorectal cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
+ fluoropyrimidine
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT04789096
Advanced
Phase 2
Recruiting
A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients with Pre-treated Advanced HER2-positive Breast Cancer (
TUGETHER
)
ERBB2 inhibitor,third generation
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
+ fluoropyrimidine
Breast cancer
HER2-positive breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ fluoropyrimidine
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ fluoropyrimidine
Pancreatic cancer
ACTRN12623001301651
Curative
Not Applicable
Recruiting
GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (
GeneScreen-5-FU
)
fluoropyrimidine
Cancer
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
+ fluoropyrimidine
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
+ fluoropyrimidine
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
+ fluoropyrimidine
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12616001112459
Curative
Phase 1 / Phase 2
Recruiting
Efficacy and Safety of Folfirinox as Neoadjuvant Chemotherapy for Resectable Gastric or Gastroesophageal junction adenocarcinoma- a run- in pilot followed by Phase 2 comparison between ECF and FOLFIRINOX –
FIG
study
Cisplatin
Epirubicin
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
anthracycline
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ fluoropyrimidine
Gastric adenocarcinoma
Gastroesophageal junction adenocarcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
ACTRN12616000554460
Curative
Phase 1
Not yet recruiting
ACES
: Adjuvant Chemotherapy in Early stage oeSophageal cancer- a feasibility study
Cisplatin
Fluorouracil
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ fluoropyrimidine
Oesophageal cancer
NCT06509906
Advanced
Phase 1
Suspended
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (
MS202650-0001
)
PARP1-selective inhibitor
+ fluoropyrimidine
Colorectal adenocarcinoma
NOT Colorectal adenocarcinoma
Solid tumour
NSW
2217 - Kogarah - St George Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06094140
Curative
Phase 2
Active not recruiting
NEO-adjuvant Chemo-Immunotherapy in Pancreatic Cancer (
NEO-IMPACT
)
Durvalumab
Filgrastim
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Pegfilgrastim
anti-PD-L1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
+ fluoropyrimidine
Pancreatic cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3030 - Heidelberg - Ballarat Austin Radiation Oncology Centre
NCT05867121
Advanced
Phase 1
Active not recruiting
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors (
GO44010
)
anti-TGF-beta monoclonal antibody
+ fluoropyrimidine
Gastric cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05840211
Advanced
Phase 3
Active not recruiting
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy (
ASCENT-07
)
anti-Trop2 antibody-drug conjugate
+ fluoropyrimidine
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05625412
Advanced
Phase 1
Active not recruiting
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors (
IM043-004
)
JNK inhibitor
anti-PD-1 monoclonal antibody
+ fluoropyrimidine
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05609370
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (
BGB-A317-LBL-007-201
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
+ fluoropyrimidine
Colorectal cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT05568095
Advanced
Phase 3
Active not recruiting
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma (
STAR-221
)
anti-PD-1 monoclonal antibody
anti-TIGIT monoclonal antibody
+ fluoropyrimidine
Adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05383352
Advanced
Phase 1
Completed
A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Agents in Adult Participants With Metastatic Pancreatic Adenocarcinoma (
SIRACUSA
)
topoisomerase inhibitor
+ fluoropyrimidine
Pancreatic adenocarcinoma
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05330429
Advanced
Phase 2
Terminated
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (
ELEVATE-CRC
)
anti-CD47 monoclonal antibody
anti-VEGF monoclonal antibody
+ fluoropyrimidine
Colorectal cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12622000378729
Curative
Phase 2
Active not recruiting
Investigating the safety and efficacy of NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer,
NEO-IMPACT
.
Durvalumab
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
Pegfilgrastim
anti-PD-L1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
+ fluoropyrimidine
Pancreatic cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ fluoropyrimidine
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
ACTRN12618001480279
Advanced
Phase 2
Status unknown
Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial (
ALT-TRACC
)
platinum-based antineoplastic agent
topoisomerase inhibitor
+ fluoropyrimidine
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Active not recruiting (7)
Not yet recruiting (3)
Status unknown (2)
Not yet recruiting (1)
Suspended (1)
Completed (1)
Terminated (1)
Recruitment Country and State
VIC (31)
NSW (27)
SA (15)
QLD (13)
WA (13)
NZ (4)
TAS (3)
ACT (2)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (5)
Phase 2 (9)
Phase 2 / Phase 3 (1)
Phase 3 (12)
Trial Type
Advanced (30)
Curative (10)
Cancer Therapy Class
PD-1/PD-L1
40%
PD-1
30%
VEGF
23%
EGFR
18%
PD-L1
15%
ERBB2
15%
Trop2
15%
TIGIT
8%
MET
5%
PARP
5%
DPD
5%
orotate phosphoribosyltransferase
5%
CDK4
5%
CDK6
5%
ERBB3
3%
CTLA4
3%
PRMT5
3%
GRPR
3%
CLDN18.2
3%
CD39
3%
KRAS
3%
KRAS G12C
3%
AKT
3%
CD40
3%
ER
3%
IL-6
3%
LIV1
3%
PI3Kalpha
3%
oestrogen axis
3%
JAK
3%
SYK
3%
PARP1-selective
3%
TGF-beta
3%
JNK
3%
LAG3
3%
CD47
3%
ALK
3%
ATR
3%
BCR-ABL1
3%
CRAF
3%
FLT3
3%
JAK1
3%
JAK2
3%
KIT
3%
PDGFR
3%
PDGFRA
3%
PI3K
3%
RAF
3%
ROS1
3%
SMO
3%
SRC
3%
VEGFR
3%
YES1
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (12)
6150 - Murdoch - Fiona Stanley Hospital (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
3021 - St Albans - Western Health - Sunshine Hospital (7)
5042 - Bedford Park - Flinders Medical Centre (7)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (6)
5011 - Woodville South - The Queen Elizabeth Hospital (5)
3199 - Frankston - Peninsula Health Frankston Hospital (5)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
3168 - Clayton - Monash Medical Centre (5)
2500 - Wollongong - Wollongong Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2109 - North Ryde - Macquarie University Hospital (4)
2065 - St Leonards - GenesisCare North Shore Private Hospital (4)
2170 - Liverpool - Liverpool Hospital (4)
3066 - Epping - Northern Hospital (4)
5112 - Elizabeth Vale - Lyell McEwin Hospital (4)
3002 - East Melbourne - Epworth Freemasons (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3004 - Melbourne, Southbank - Alfred Health (3)
3011 - Footscray - Footscray Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
6009 - Nedlands - One Clinical Research (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (2)
7000 - Hobart - ICON Cancer Care Hobart (2)
2605 - Garran - The Canberra Hospital (2)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
2217 - Kogarah - St George Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
2217 - Kogarah - St George Private Hospital (1)
3030 - Heidelberg - Ballarat Austin Radiation Oncology Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2650 - Wagga Wagga - Riverina Cancer Care Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
4217 - Benowa - Pindara Private Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Upper gastrointestinal cancer
Breast cancer
Colorectal cancer
Lower gastrointestinal cancer
Pancreatobiliary cancer
Thoracic cancer
Pancreatic cancer
Gastroesophageal cancer
Gastric cancer
Oesophageal cancer
Breast adenocarcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Gastric adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Biliary tract cancer
Hepatobiliary cancer
Head and neck cancer
Colorectal adenocarcinoma
HER2-positive breast cancer
Triple-negative breast cancer
Head and neck squamous cell carcinoma
HER2-positive gastric cancer
Bladder cancer
Cervical cancer
Clear cell renal cell carcinoma
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Ovarian cancer
Urogenital cancer
Viral-related cancer
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
Skin cancer
Adenocarcinoma
Carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy